Skip Navigation

European Heart Journal 1980 1(1):25-29;
Copyright © 1980 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by MATHEY, D.
Right arrow Articles by BLEIFELD, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MATHEY, D.
Right arrow Articles by BLEIFELD, W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1980 The European Society of Cardiology

Acute and chronic effects of oral hydralazine on left ventricular pump function and renal hemodynamics in chronic left heart failure

D. MATHEY, P. MANRATH, J. POLSTER, G. WITTE, R. MONTZ and W. BLEIFELD

Departments of Cardiology and Nuclear Medicine, University Hospital Eppendorf Hamburg, W. Germany

Received 5 November 1979; .

To test the acute and chronic, effects, of oral hydralazine (HD) on left ventricular (LV) pump function and renal hemodynamics, we administered it to patients with chronic left heart failure. After 6 days of HD- therapy (n = 12), there was a striking increase in cardiac index (P < 0.001) averaging 50% of control, which was fully maintained over a 6 month, period of chronic HD-therapy (n = 6, P < 0.001). Improvement in pump function was associated with a marked, chronically sustained fall in systemic vascular resistance (–43% after 6 days, P < 0.001, –40% after 6 months, P < 0.01). Despite the significant increase in cardiac index, renal perfusion did not change acutely under HD. After 6 months, however, a 32% increase in renal perfusion was found accompanying the persistent improvement in cardiac performance (P < 0.01).

Our data suggest that oral HD is equally effective during acute and chronic application in patients with left heart failure. After short-term HD therapy, no increase in renal perfusion occurs, perhaps due to renal vasoconstriction involving, the renin-angiotensin system. Chronically, however, HD improves renal perfusion, as it controls heart failure.

Key Words: Hydralazine • left heart failure


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.